News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.

Scientists have found that most gastric tumors harbor genetic alterations that may respond to targeted therapies

Background. Gastric cancer (GC) is a major global cancer burden and the second most common cause of global cancer-related deaths. The addition of anti-ERBB2 (HER2) targeted therapy to chemotherapy improves survival forERBB2-amplified advanced GC patients; however, the majority of GC patients do not harbor this alteration and thus cannot benefit from targeted therapy under current practice paradigms.